HomeLSTA • NASDAQ
add
Lisata Therapeutics Inc
Previous close
$2.05
Day range
$1.99 - $2.13
Year range
$1.81 - $4.20
Market cap
18.17M USD
Avg Volume
106.98K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 4.41M | -17.28% |
Net income | -4.25M | 13.81% |
Net profit margin | — | — |
Earnings per share | -0.49 | 16.95% |
EBITDA | -4.37M | 17.45% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 19.00M | -47.02% |
Total assets | 21.76M | -43.04% |
Total liabilities | 4.64M | -2.58% |
Total equity | 17.12M | — |
Shares outstanding | 8.82M | — |
Price to book | 1.04 | — |
Return on assets | -47.04% | — |
Return on capital | -58.17% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -4.25M | 13.81% |
Cash from operations | -3.34M | -32.72% |
Cash from investing | 5.15M | 181.68% |
Cash from financing | 353.00K | — |
Net change in cash | 2.16M | 124.62% |
Free cash flow | -1.84M | -115.02% |
About
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Founded
1980
Headquarters
Website
Employees
26
